Test 3: molec therapeutics

Card Set Information

Author:
dmatta
ID:
37296
Filename:
Test 3: molec therapeutics
Updated:
2010-10-02 21:13:09
Tags:
molec therapeutics
Folders:

Description:
test 3 molecu therapeutics
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user dmatta on FreezingBlue Flashcards. What would you like to do?


  1. Drug List:
    • Recombinant Proteins:
    • -- Etanercept

    • Monoclonal antibodies:
    • -- Trastuzumab
    • -- Rituximab
    • -- Abciximab
    • -- Bevacizumab

    • Immunotoxins:
    • -- Denileukin Difitox

    • Radionuclide Conjugates:
    • -- Ibritumomab Tiuxetan
    • -- Bapromab penditide
    • -- imciromab penetate

    • Antisense oligonucleotides:
    • --fomiversin
    • --pegaptinib
  2. Etanercept (recombinant protein)
    • MOA:
    • Binds to TNF-anti inflammatory

    • Coverage:
    • Treatment for arthritis, break cycle of inflammation by binding TNF.
    • Acts as a decoy
  3. Trastuzumab (monoclonal antibody)
    • MOA:
    • Herceptin-, anti epidermal growth factor receptor 2
    • - Prevents receptor activation

    • Coverage:
    • Slows breast tumor growth
  4. Bevacizumab (Monoclonal antibody)
    • MOA:
    • Blocks VEGF and slows tumor growth
  5. Rituximab (monoclonal antibody)
    • MOA:
    • Clears B cells by targetting CD20 antigen

    • Coverage:
    • Treat non-Hodgkin B cell lymphoma (NHL). Also approved for rheumatoid arthritis, supressing B cell function and
    • the production of Ab against proteins usually found in the joints
  6. Abciximab (monoclonal antibody)
    • MOA:
    • Minimizes platelet thrombosis and artery re-stenosis
  7. Denileukin-difitox (immunotoxin)
    • MOA:
    • Recombinant fusion of protein IL-2 (targeting) and toxin domain from diphtheria.
    • -- targets ribosomes

    • Coverage:
    • Treats T cell lymphomas expressing IL-2 receptors
    • -- Replenish T cell from marrow after T cell depletion
  8. Ibritumomab tiuxetan (radionuclide conjugate)
    -- short half life, beta emitter.
    • MOA:
    • 131I or 90Yt is antiCD20 conjugated with 90Yt

    • Coverage:
    • Low grade lymphoma
    • follifular lymphoma
    • transformed NHL (relapsed or refractory)
  9. Capromab penditide (radionuclide conjugate)
    -- short half life, beta emitters
    • MOA:
    • 111In used for nuclear imaging

    • Coverage:
    • Prostate tumor specific antibody.
    • Detect metastases
  10. Imciromab pentetate (radionuclide conjugate)
    -- short half life, beta emitter
    • MOA:
    • 111In for nuclear imaging

    • Coverage:
    • Detects cardiac actin: reveals sites of myocardial tissue damage
  11. Fomiversin (antisense oligonucleotide)
    • MOA:
    • Phosphorothioate oligonucleotide against IE2 gene of cytomegalovirus
    • -- blocks CMV replication
    • Coverage:
    • Treat CMV retinitis in AIDS patients
    • administered intraocularly to achieve high concentrations (DNA)
  12. Pegaptinib (antisense oligonucleotide)
    • MOA:
    • Directed against VEGF (blocks neovascularization)

    • Coverage:
    • Wet macular degeneration

What would you like to do?

Home > Flashcards > Print Preview